Eclampsia and Neonatal Loss in a Patient With Primary Antiphospholipid Syndrome, Factor V Leiden, and Methylenetetrahydrofolate Reductase (MTHFR) Mutations: A Rare Thrombophilic Triad

原发性抗磷脂综合征、V因子Leiden突变和亚甲基四氢叶酸还原酶(MTHFR)突变患者发生子痫和新生儿死亡:一种罕见的血栓形成三联征

阅读:1

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by an increased risk of thrombosis and pregnancy complications, including placental insufficiency, preeclampsia, and fetal loss. The coexistence of APS with both factor V Leiden and methylenetetrahydrofolate reductase (MTHFR) mutations is exceptionally rare and may further elevate the risk of adverse outcomes. A 23-year-old primigravida developed eclampsia at eight months' gestation and underwent an emergency cesarean section; unfortunately, her newborn died a few days later. Laboratory evaluation confirmed APS with a positive lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I, as well as the presence of factor V Leiden and MTHFR mutations. Hydroxychloroquine, aspirin, and low-molecular-weight heparin therapy were initiated. This case should encourage physicians to broaden their initial screening laboratory tests and consider implementing more comprehensive testing in patients who present with early and severe pre-eclampsia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。